CTVP方案治疗侵袭性B细胞非霍奇金淋巴瘤85例临床疗效分析  

CTVP Regimen in the Treatment for Non-Hodgkin's Lymphoma

作　　者：侯芸[1] 王华庆[1] 张会来[1] 钱正子[1] 周世勇[1] 邱立华[1] 付凯[1] 刘贤明[1] 崔秀珍[1] 

机构地区：[1]天津医科大学附属肿瘤医院淋巴肿瘤科,中美淋巴血液肿瘤诊治中心,天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2011年第18期1099-1102,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:评估含吡喃阿霉素(THP)及长春地辛(VDS)的CTVP方案治疗非霍奇金淋巴瘤(NHL)的近期疗效、远期生存及不良反应。方法:收集2000年1月至2005年12月间应用CTVP方案治疗的资料完整的侵袭性B细胞NHL患者85例,分析其近期疗效、远期生存及不良反应。结果:85例患者中初治74例,复治11例,全部病例均可评价疗效,一线治疗CR 55.4%,有效率68.9%,临床受益率86.0%,二线治疗有效率45.5%,临床受益率63.6%。随访至2009年12月,中位随访时间为69个月(6～102个月),1、3、5年生存率分别为82.4%、71.5%和60.7%,中位生存期75个月(6～99个月),骨髓抑制、胃肠道反应、乏力、外周神经毒性和脱发为主要不良反应。结论:采用含THP和VDS的CTVP方案治疗NHL疗效较好,毒性较低,远期生存率较高,值得临床进一步研究。Objective： To analyze the efficacy and toxicity of the CTVP regimen in the treatment of non-Hodgkin＇s lymphoma （ NHL ）. Methods： From January 2000 to December 2005, 85 patients with NHL were treated with the CTVP regimen with or without ra-diotherapy for the involved field. The clinical characteristics, response, toxicity, and long-term survival results were analyzed retrospectively. Results： Of the 85 patients, 74 received initial treatment, 11 were treated again. A total of 85 patients were eligible. The clinicalbenefit rate of the first-line therapy was 86.0%, the response rate was 68.9%, and the complete response rate was 55.4%. The clinical benefit rate of the second-line therapy was 63.6%; the response rate was 45.5%. The median follow-up duration in this series was 69months （ range： 6-102 months ）. The overall 1-, 3-, 5-year survival rates were 82.4%, 71.5%, and 60.7%, respectively, with a median survival time of 75 months （ 6-99 ）. The major toxic effects of the regimen were myelosuppression, GI toxicity, fatigue, neurotoxicity,and alopecia. Conclusion： The CTVP regimen is effective and well tolerated by the non-Hodgkin＇s lymphoma patients.

关 键 词：非霍奇金淋巴瘤 长春地辛 吡喃阿霉素 总生存期 

分 类 号：R733.1[医药卫生—肿瘤]